COMMUNIQUÉS West-GlobeNewswire

Yatiri Bio Enters Exclusive Option to In-License Agreement with Oscotec for Denfivontinib in AML
24/03/2026
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop [...]
Transactions in connection with share buy-back program
24/03/2026
Company announcement no. 6 - 26 24 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
iDEL Therapeutics Appoints Claudia Ulbrich as Chair of its Board of Directors
24/03/2026
Dortmund, Germany, March 24, 2026 – iDEL Therapeutics today announced the appointment of accomplished biopharmaceutical executive Claudia Ulbrich, MD, as the Chair of its Board of Directors. Dr. Ulbrich brings over 25 [...]
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
24/03/2026
First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and [...]
Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »
24/03/2026
Mise en ligne du document «Q1 2026 aide-mémoire » Paris, France – 24 mars 2026 . Sanofi annonce la mise en ligne de son « Q1 2026 aide-mémoire » sur la page « Investisseurs » de son site internet. Résultats du premier [...]
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
24/03/2026
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
24/03/2026
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results showing over four times [...]
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures Proceeds will [...]
Press release: Availability of the Q1 2026 aide-mémoire
24/03/2026
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026 . Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results [...]
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
24/03/2026
Focused on selective acquisitions of high-quality companies in strategic industrial sectors MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge 1 , a strategic [...]
Phonak AI-Powered Hearing Aids Recognized with 2026 Artificial Intelligence Excellence Awards
24/03/2026
Phonak Virto R Infinio and Phonak Infinio Ultra Sphere honored for advancing real-world hearing performance through AI innovation STÄFA, Switzerland, March 24, 2026 (GLOBE NEWSWIRE) -- Phonak , a global leader in [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse
24/03/2026
Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients atteints d’une forme [...]
Idorsia announces the nomination of three candidates for election to the Board of Directors
24/03/2026
Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026 All Board members – current and [...]
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
24/03/2026
NESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the “Shares”) at a [...]
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
23/03/2026
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/03/2026
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, [...]
Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
23/03/2026
Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended [...]
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
23/03/2026
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice [...]
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
23/03/2026
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million [...]

Pages